Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

• Published in: Anticancer research 2022-04, Vol.42 (4), p.1987-1995
• Main Authors: Svaton, Martin, Bratova, Monika, Koubkova, Leona, Fischer, Ondrej, Melichar, Bohuslav, Hrnciarik, Michal, Dolezal, Daniel, Bilek, Ondrej, Krejci, Jana, Drosslerova, Marie, Dlouha, Zdenka, Blazek, Jiri, Majkova, Petra, Brozova, Lucie, Stastny, Marek
• Format: Article
• Language: English
• Subjects: Bevacizumab; Cancer; Carboplatin; Chemotherapy; Cisplatin; Immunotherapy; Lung cancer; Non-small cell lung carcinoma; Paclitaxel; Patients; Response rates; Small cell lung carcinoma; Survival; Taxanes; Vinorelbine
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.15677

This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens. The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treated adenocarcinomas in second and higher lines of treatment. In relation to objective response rate, progression-free interval, and overall survival, three comparisons of patient were made: A: Those treated in first line with cisplatin and pemetrexed versus carboplatin with paclitaxel or vinorelbine; B: treatment with cisplatin and pemetrexed versus carboplatin with paclitaxel/vinorelbine and bevacizumab; and C: treatment in previous lines with pemetrexed (first-line cisplatin and pemetrexed plus those treated in second line with pemetrexed) versus treatment with taxane (first-line carboplatin and paclitaxel only plus those treated with second-line docetaxel). We observed no differences in objective response rate or progression-free survival between patients treated with the stated chemotherapeutic regimens. We observed a trend towards better overall survival for patients treated with carboplatin plus taxanes or vinorelbine with/without bevacizumab. From our overall survival data, a chemotherapeutic regimen of carboplatin plus taxanes or vinorelbine with/without bevacizumab might be a better partner for immunotherapy than a cisplatin and pemetrexed-based one.